Links

Homepage

Stock List

Search by Ticker

News

Login

Ligand Pharmaceuticals Incorpor (NasdaqGM:LGND)
Stock Analysis

LGND119.08
▲ 1.62%1.9

Stock Analysis

The following stock analysis is based on 7.8 years of data (i.e. since Oct 31, 2012). All the stock history has been downloaded.

Stock Exchange

Ligand Pharmaceuticals Incorpor trades on the NasdaqGM exchange in USD dollars.

Sector

It is in the sector.

Current Status of Ligand Pharmaceuticals Incorpor

It is currently trading at $119.08 ($117.18 the previous day).

Financials

The next reporting date is in -18478 days (1970 01 01).

CNN estimates profits for the upcoming quarter will be $0.94 per share ($36.8M). The current Canada / US exchange rate is 1.33745.



Over the past 12 months, $175495 worth of shares have been purchased and $2808992 worth of shares have been sold by insiders.

Will This Trend Continue?

The year over year average increase is 1.5% per year assuming steady exponential growth. The actual 5 year average is 13.46. Details on the individual increase in one year intervals is provided below.

Past PerformanceAverage PricePercent Change
1 year99.024970491803-37.3- Below Average
2 year158.05334841629-2.2- Below Average
3 year161.6874895397548.7+ Above Average
4 year108.760244897962.6- Below Average
5 year105.972075471755.5+ Above Average
Ligand Pharmaceuticals Incorpor is projected by analysts to get to $172.50 within the next 12 months (44.9%), but preticted targets range from as high as $229.00 (92.3%) and as low as $134(12.5%).

Risk

The worst drop it has had in recent years is -75.7%. It has a up and down shape to the stock curve, which means the stock can have significant gains followed by losses. Good for day trading, but needs to be watched if held for any significant amount of time.

Stock shape test

DAYS AG0PRICE
10122.04DROPPING
30111.64RISING
60100.78RISING
150106.63DROPPING
36595.06RISING
800189.25DROPPING
1200104.39RISING
160097.22RISING
200056.56RISING


With an average increase of 1.5% year over year, if Ligand Pharmaceuticals Incorpor is bought at the worst time, Stockmarketizer analysts estimate it will take 605.6 months before the stock will recover to the original purchase price.

Tradingview BuySell Widget

Yahoo News Feed

Ligand Trounces Q2 Estimates by Helping Companies Make COVID-19 Drug Remdesivir

Mon, 03 Aug 2020 18:10:00 Ligand Pharmaceuticalsand' (NASDAQ: LGND) big slide in March was only short-lived. Its shares have rebounded nicely over the last several months and came into this week up 12% year to date. The biotech announced its second-quarter results before the market opened ...... Read Full Article

Ligand Pharmaceuticals Inc (LGND) Q2 2020 Earnings Call Transcript

Mon, 03 Aug 2020 18:00:25 LGND earnings call for the period ending June 30, 2020.... Read Full Article

Ligand Pharmaceuticals (LGND) Q2 Earnings and Revenues Beat Estimates

Mon, 03 Aug 2020 12:55:12 Ligand (LGND) delivered earnings and revenue surprises of 53.85% and 46.78%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?... Read Full Article

Ligand Reports Second Quarter 2020 Financial Results

Mon, 03 Aug 2020 11:30:00 Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ending June 30, 2020 and provided an operating forecast and program updates. Ligand management will host a conference call with slides today beginning at 8:30 a.m. Eastern ...... Read Full Article

The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings

Sun, 02 Aug 2020 15:08:50 Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.COVID-19 news flow continued to pour in, with big pharma tie-ups flaunting positive tidings. In the biggest ever coronavirus ...... Read Full Article

Ligand’s Second Quarter Financial Results to be Reported August 3rd

Thu, 16 Jul 2020 20:28:00 Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report second quarter 2020 financial results on August 3, 2020. Ligand’s CEO John Higgins, President and COO Matt Foehr, and Executive Vice President and CFO Matt Korenberg will host the ...... Read Full Article

Functional, Human Antibodies Targeting SARS-CoV-2 Discovered Using IPA's Proprietary B cell Select™ and Single Step Cloning Hybridoma Technologies

Mon, 13 Jul 2020 11:51:00 VICTORIA , July 13, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (IPA.V) (IPATF) (TQB2.F), a leader in full-service, therapeutic antibody discovery and development, today announced the identification of additional, human lead candidate antibodies generated against SARS-CoV-2, also demonstrating ...... Read Full Article

Were Hedge Funds Right About Ligand Pharmaceuticals Inc. (LGND)?

Sun, 12 Jul 2020 20:16:32 Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge fundsand' and successful investorsand' positions as of the end of the ...... Read Full Article

Sermonix Pharmaceuticals to Collaborate With Eli Lilly and Company in Studying Combination of Lasofoxifene and Lilly’s CDK 4 and 6 Inhibitor, Abemaciclib, in Metastatic Breast Cancer

Wed, 08 Jul 2020 14:00:10 The multicenter Phase 2 trial, Sermonix’s Evaluation of Lasofoxifene and Abemaciclib in ESR1 Mutations, is projected to begin enrollment in Q3 2020. COLUMBUS, Ohio, July 08, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of ...... Read Full Article

LGND or RGEN: Which Is the Better Value Stock Right Now?

Fri, 03 Jul 2020 15:40:03 LGND vs. RGEN: Which Stock Is the Better Value Option?... Read Full Article

IPA Confirms Discovery of Fully Human, Potent, Neutralizing Antibodies Targeting SARS-CoV-2

Mon, 29 Jun 2020 16:48:00 IPA Confirms Discovery of Fully Human, Potent, Neutralizing Antibodies Targeting SARS-CoV-2... Read Full Article

Ascendis Submits BLA to FDA for TransConhGH in Pediatric GHD

Mon, 29 Jun 2020 15:44:03 Ascendis Pharma (ASND) submits BLA to the FDA for TransConhGH for the treatment of pediatric growth hormone deficiency.... Read Full Article

Vertexand's Triple Combo Cystic Fibrosis Pill Gets CHMP Backing

Mon, 29 Jun 2020 13:12:01 Vertex (VRTX) is seeking approval in Europe for its triple combo pill, Kaftrio in combination with Kalydeco to treat cystic fibrosis in patients aged 12 and older with most common genotypes.... Read Full Article

Ligand Announces an Expansion of Vernalis Collaboration with Servier for Research on Novel Oncology Targets

Mon, 15 Jun 2020 12:30:00 Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that Vernalis Research, a Ligand company, has expanded its oncology research collaboration with Servier, an international pharmaceutical company based in France, to jointly identify and enable new therapeutic targets.... Read Full Article

Why Is Ligand (LGND) Up 16.3% Since Last Earnings Report?

Fri, 05 Jun 2020 15:31:03 Ligand (LGND) reported earnings 30 days ago. Whatand's next for the stock? We take a look at earnings estimates for some clues.... Read Full Article

Ligand Pharmaceuticals Shows Improved Relative Price Performance; Still Shy Of Benchmark

Wed, 03 Jun 2020 22:43:00 Ligand Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating... Read Full Article

Ligand CEO Issues Letter to Captisol Customers

Mon, 01 Jun 2020 20:53:00 Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that Chief Executive Officer John Higgins issued a letter to Ligand’s Captisol® customers. The full text of that letter is as follows:... Read Full Article

LGND or TECH: Which Is the Better Value Stock Right Now?

Mon, 01 Jun 2020 15:40:03 LGND vs. TECH: Which Stock Is the Better Value Option?... Read Full Article

Ligand Announces Icagen’s Expansion of Collaboration with Roche to Develop and Commercialize Therapies for Neurological Diseases

Fri, 29 May 2020 12:00:00 Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Icagen, a Ligand Company, announced today the expansion of Icagen’s license agreement with Roche to develop and commercialize small molecule ion channel modulators for the treatment of neurological disorders, by adding a second ...... Read Full Article
<